These studies tested for a facilitatory interaction between noradrenergic and excitatory amino acid mechanisms controlling oxytocin (OT) release in the lactating rat. Lactating females were cannulated in the supraoptic nucleus of the hypothalamus (SON) or into the third ventricle and treated with the alpha 1-agonist phenylephrine (PHE) or the glutamate receptor agonist alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), either alone or together. Treatment with PHE increased plasma OT dose dependently after microinjection into the SON area; strong stimulation also occurred after third ventricle injection of the drug. AMPA caused dose-dependent increases in plasma OT after SON injection. Coinjection of an ineffective or submaximally effective dose of AMPA and a submaximally stimulating dose of PHE produced synergistic OT discharges. OT release in response to the combination of PHE plus AMPA could be abolished by pretreatment/cotreatment with either an alpha 1-adrenergic antagonist or an AMPA receptor antagonist. Moreover, the OT secretory response to the alpha 1-adrenergic agonist PHE alone was attenuated by blockade of AMPA receptors, whereas the OT secretory response to the glutamate agonist AMPA alone was attenuated by blockade of alpha 1-adrenergic receptors. These findings suggest an interaction between norepinephrine and glutamate that may involve pre- and/or postsynaptic mechanisms. As disruption of either noradrenergic or glutamatergic mechanisms is known to impair suckling-induced OT release, the cooperative action of transmitters active at alpha 1-adrenergic and AMPA receptors may be important for the milk ejection reflex.

Download full-text PDF

Source
http://dx.doi.org/10.1210/endo.133.6.7694847DOI Listing

Publication Analysis

Top Keywords

alpha 1-adrenergic
20
oxytocin release
8
release lactating
8
lactating rat
8
excitatory amino
8
amino acid
8
acid mechanisms
8
third ventricle
8
ampa
8
secretory response
8

Similar Publications

Background: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.

View Article and Find Full Text PDF

Lower body negative pressure (LBNP) has been used for decades in humans to model arterial baroreceptor unloading and represents a powerful tool for evaluating cardiovascular responses to orthostatic challenge. However, LBNP studies in animals have been limited to conditions of anesthesia or sedation, where cardiovascular reflexes are altered. Given the consequent uncertainties, the usefulness of LBNP studies in these preclinical models has been severely hampered.

View Article and Find Full Text PDF

The cerebellum is activated by noxious stimuli and pathological pain but its role in noxious information processing remains unknown. Here, we show that in mice, cutaneous noxious electrical stimuli induced noradrenaline (NA) release from locus coeruleus (LC) terminals in the cerebellar cortex. Bergmann glia (BG) accumulated these LC-NA signals by increasing intracellular calcium in an integrative manner ('flares').

View Article and Find Full Text PDF

Although angiotensin 1-7 (Ang 1-7) and its role as a part of the "protective" axis of the renin-angiotensin system are well described in the literature, the mechanisms of its angiotensin II-like pressor and tachycardic effects following its acute central administration are not fully understood. It was the aim of the present study to examine which receptors contribute to the aforementioned cardiovascular effects. Ang 1-7 and antagonists for glutamate, GABA, vasopressin, thromboxane A (TP), α-adrenergic, and P2X purinoceptors or modulators of oxidative stress were injected into the paraventricular nucleus of the hypothalamus (PVN) of urethane-anesthetized male Wistar rats.

View Article and Find Full Text PDF

Autonomic dysfunction is associated with cardiovascular and neurological disease, including hypertension, heart failure, anxiety, and stress-related disorders. Prior studies demonstrated that late gestation exposure to dexamethasone (DEX) resulted in female-biased increases in stress-responsive mean arterial pressure (MAP) and heart rate (HR), suggesting a role for glucocorticoid-mediated programming of autonomic dysfunction. The present study investigated the influence of sympathetic (SYM) or parasympathetic (PS) blockade on cardiovascular function in male and female rat offspring of mothers injected with DEX (gestation days [GD]18-21).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!